SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001626199-21-000154
Filing Date
2021-12-16
Accepted
2021-12-16 08:14:46
Documents
12
Period of Report
2021-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K alpn-20211215.htm   iXBRL 8-K 49637
  Complete submission text file 0001626199-21-000154.txt   192836

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alpn-20211215.xsd EX-101.SCH 1951
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alpn-20211215_lab.xml EX-101.LAB 24849
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alpn-20211215_pre.xml EX-101.PRE 13082
5 EXTRACTED XBRL INSTANCE DOCUMENT alpn-20211215_htm.xml XML 11265
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 211496072
SIC: 2834 Pharmaceutical Preparations